Company intelligence / Profile preview
Takara Bio Inc.
Kusatsu-Shi, Shiga, Japantakara-bio.com ↗
- Ownership
- Public · 4974
- Employees
- ~1838
- Development stage
- Other
01
Overview
Takara Bio has been conducting clinical trials of gene therapy products since 2008 and was the first company in Japan to do so. They operate a CDMO facility called the Center for Gene and Cell Processing (CGCP) for development, manufacturing, and quality testing of gene therapy products.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Gene therapycell therapyregenerative medicine
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
Gap Junction Therapeutics, Inc. (for co-developing adeno-associated virus vector gene therapy)
Beyond the preview
Go deeper on Takara Bio Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Takara Bio Inc..